Literature DB >> 17557953

Depression, immunity, and survival in patients with hepatobiliary carcinoma.

Jennifer L Steel1, David A Geller, T Clark Gamblin, Marion C Olek, Brian I Carr.   

Abstract

PURPOSE: The aims of the present study were to assess the prevalence of depressive symptoms at diagnosis, test the association between depressive symptoms and survival, and preliminarily test a mediational model of depression, immunity, and survival in patients with hepatobiliary carcinoma (HBC). PATIENTS AND METHODS: One hundred one patients diagnosed with HBC were prospectively studied. Depressive symptoms were measured at diagnosis using the Center for Epidemiological Studies Depression Scale (CES-D). Sociodemographic and disease-specific data were gathered from the patients' charts. In a subsample of patients, stress; alcohol, tobacco, and drug use; sleep quality; physical activity; social support; natural killer (NK) cell number and cytotoxicity; and plasma levels of interleukin (IL) -4, IL-5, tumor necrosis factor alpha, and interferon gamma were measured. Survival was measured from date of diagnosis to death.
RESULTS: At diagnosis, 37% of patients reported a CES-D score of > or = 16 (clinical range). Using Cox regression analysis, sociodemographic and disease-specific variables and CES-D score significantly predicted survival (Breslow chi2 = 32.4, P = .006). Only vascular invasion (P = .001) and CES-D score > or = 16 (P = .03) were significant predictors. In a subsample of 23 patients, patients who reported a CES-D score of > or = 16 were found to have significantly lower NK cell numbers than patients who reported a CES-D score of less than 16 (F1,21 = 9.39, P = .003). A robust trend was found in which NK cell number was associated with survival. A mediational model linking depressive symptoms and survival, with NK cell number as a mediator, was preliminarily supported.
CONCLUSION: Secondary to the high prevalence of depressive symptoms and impact on survival, psychological and pharmacologic interventions should be designed and implemented in patients diagnosed with HBC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17557953     DOI: 10.1200/JCO.2006.06.4592

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  48 in total

Review 1.  Biobehavioral factors and cancer progression: physiological pathways and mechanisms.

Authors:  Susan K Lutgendorf; Anil K Sood
Journal:  Psychosom Med       Date:  2011-10-21       Impact factor: 4.312

2.  Distress-the 6th vital sign.

Authors:  D Howell; K Olsen
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

Review 3.  Sleep disturbance, inflammation and depression risk in cancer survivors.

Authors:  Michael R Irwin; Richard E Olmstead; Patricia A Ganz; Reina Haque
Journal:  Brain Behav Immun       Date:  2012-05-24       Impact factor: 7.217

Review 4.  Host factors and cancer progression: biobehavioral signaling pathways and interventions.

Authors:  Susan K Lutgendorf; Anil K Sood; Michael H Antoni
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

Review 5.  Biobehavioral influences on cancer progression.

Authors:  Erin S Costanzo; Anil K Sood; Susan K Lutgendorf
Journal:  Immunol Allergy Clin North Am       Date:  2011-02       Impact factor: 3.479

6.  Prospective Analyses of Cytokine Mediation of Sleep and Survival in the Context of Advanced Cancer.

Authors:  Jennifer L Steel; Lauren Terhorst; Kevin P Collins; David A Geller; Yoram Vodovotz; Juliana Kim; Andrew Krane; Michael Antoni; James W Marsh; Lora E Burke; Lisa H Butterfield; Frank J Penedo; Daniel J Buysse; Allan Tsung
Journal:  Psychosom Med       Date:  2018-06       Impact factor: 4.312

7.  Depressive Symptoms in Patients Scheduled for Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery: Prospective Associations With Morbidity and Mortality.

Authors:  Carissa A Low; Dana H Bovbjerg; Steven Ahrendt; Sara Alhelo; Haroon Choudry; Matthew Holtzman; Heather L Jones; James F Pingpank; Lekshmi Ramalingam; Herbert J Zeh; Amer H Zureikat; David L Bartlett
Journal:  J Clin Oncol       Date:  2016-02-22       Impact factor: 44.544

Review 8.  Pre-treatment effects of peripheral tumors on brain and behavior: neuroinflammatory mechanisms in humans and rodents.

Authors:  Andrew Schrepf; Susan K Lutgendorf; Leah M Pyter
Journal:  Brain Behav Immun       Date:  2015-05-06       Impact factor: 7.217

9.  Depression and cancer mortality: a meta-analysis.

Authors:  M Pinquart; P R Duberstein
Journal:  Psychol Med       Date:  2010-01-20       Impact factor: 7.723

10.  Pancreatic cancer and depression: myth and truth.

Authors:  Martina Mayr; Roland M Schmid
Journal:  BMC Cancer       Date:  2010-10-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.